In acute myeloid leukemia, molecular genetics abnormalities, particularly NPM1 and FLT3 mutations, have a recognized prognostic role in the ELN risk classification and guide treatment decisions, especially since the availability of FLT3-targeted drugs. Here, NPM1 is linked to acute myeloid leukemia.